726 related articles for article (PubMed ID: 32759302)
1. The role of gut microbiota in cancer treatment: friend or foe?
Cheng WY; Wu CY; Yu J
Gut; 2020 Oct; 69(10):1867-1876. PubMed ID: 32759302
[TBL] [Abstract][Full Text] [Related]
2. Modulation of Gut Microbiota to Enhance Effect of Checkpoint Inhibitor Immunotherapy.
Wu J; Wang S; Zheng B; Qiu X; Wang H; Chen L
Front Immunol; 2021; 12():669150. PubMed ID: 34267748
[TBL] [Abstract][Full Text] [Related]
3. The Role of Gut Microbiota in Modulating Tumor Growth and Anticancer Agent Efficacy.
Kim J; Lee HK
Mol Cells; 2021 May; 44(5):356-362. PubMed ID: 33972463
[TBL] [Abstract][Full Text] [Related]
4. Modulation of gut microbiota to overcome resistance to immune checkpoint blockade in cancer immunotherapy.
Huang J; Jiang Z; Wang Y; Fan X; Cai J; Yao X; Liu L; Huang J; He J; Xie C; Wu Q; Cao Y; Leung EL
Curr Opin Pharmacol; 2020 Oct; 54():1-10. PubMed ID: 32619934
[TBL] [Abstract][Full Text] [Related]
5. The Role of Gut Microbiota in Overcoming Resistance to Checkpoint Inhibitors in Cancer Patients: Mechanisms and Challenges.
Bouferraa Y; Chedid A; Amhaz G; El Lakkiss A; Mukherji D; Temraz S; Shamseddine A
Int J Mol Sci; 2021 Jul; 22(15):. PubMed ID: 34360802
[TBL] [Abstract][Full Text] [Related]
6. Pharmacomicrobiomics: exploiting the drug-microbiota interactions in anticancer therapies.
Panebianco C; Andriulli A; Pazienza V
Microbiome; 2018 May; 6(1):92. PubMed ID: 29789015
[TBL] [Abstract][Full Text] [Related]
7. Immunogenic cell death: A link between gut microbiota and anticancer effects.
Chen W; Wang S; Wu Y; Shen X; Guo Z; Li Q; Xing D
Microb Pathog; 2020 Apr; 141():103983. PubMed ID: 31954823
[TBL] [Abstract][Full Text] [Related]
8. Gut microbiota and cancer: How gut microbiota modulates activity, efficacy and toxicity of antitumoral therapy.
Gori S; Inno A; Belluomini L; Bocus P; Bisoffi Z; Russo A; Arcaro G
Crit Rev Oncol Hematol; 2019 Nov; 143():139-147. PubMed ID: 31634731
[TBL] [Abstract][Full Text] [Related]
9. Can the microbiota predict response to systemic cancer therapy, surgical outcomes, and survival? The answer is in the gut.
El Bairi K; Jabi R; Trapani D; Boutallaka H; Ouled Amar Bencheikh B; Bouziane M; Amrani M; Afqir S; Maleb A
Expert Rev Clin Pharmacol; 2020 Apr; 13(4):403-421. PubMed ID: 32308061
[TBL] [Abstract][Full Text] [Related]
10. Trial watch : the gut microbiota as a tool to boost the clinical efficacy of anticancer immunotherapy.
Daillère R; Derosa L; Bonvalet M; Segata N; Routy B; Gariboldi M; Budinská E; De Vries IJM; Naccarati AG; Zitvogel V; Caldas C; Engstrand L; Loilbl S; Fieschi J; Heinzerling L; Kroemer G; Zitvogel L
Oncoimmunology; 2020 Jun; 9(1):1774298. PubMed ID: 32934879
[TBL] [Abstract][Full Text] [Related]
11. Fecal microbiota transplantation in cancer management: Current status and perspectives.
Chen D; Wu J; Jin D; Wang B; Cao H
Int J Cancer; 2019 Oct; 145(8):2021-2031. PubMed ID: 30458058
[TBL] [Abstract][Full Text] [Related]
12. Towards modulating the gut microbiota to enhance the efficacy of immune-checkpoint inhibitors.
Simpson RC; Shanahan ER; Scolyer RA; Long GV
Nat Rev Clin Oncol; 2023 Oct; 20(10):697-715. PubMed ID: 37488231
[TBL] [Abstract][Full Text] [Related]
13. Modulatory effects of gut microbiome in cancer immunotherapy: A novel paradigm for blockade of immune checkpoint inhibitors.
Rezasoltani S; Yadegar A; Asadzadeh Aghdaei H; Reza Zali M
Cancer Med; 2021 Feb; 10(3):1141-1154. PubMed ID: 33369247
[TBL] [Abstract][Full Text] [Related]
14. Elucidating the gut microbiota composition and the bioactivity of immunostimulatory commensals for the optimization of immune checkpoint inhibitors.
Daillère R; Routy B; Goubet AG; Cogdill A; Ferrere G; Alves-Costa Silva C; Fluckiger A; Ly P; Haddad Y; Pizzato E; Thelemaque C; Fidelle M; Mazzenga M; Roberti MP; Melenotte C; Liu P; Terrisse S; Kepp O; Kroemer G; Zitvogel L; Derosa L
Oncoimmunology; 2020 Jul; 9(1):1794423. PubMed ID: 32934888
[TBL] [Abstract][Full Text] [Related]
15. Toll-like receptors in the pathogenesis of chemotherapy-induced gastrointestinal toxicity.
Cario E
Curr Opin Support Palliat Care; 2016 Jun; 10(2):157-64. PubMed ID: 26986508
[TBL] [Abstract][Full Text] [Related]
16. The impact of tumor and gut microbiotas on cancer therapy: Beneficial or detrimental?
Hekmatshoar Y; Rahbar Saadat Y; Hosseiniyan Khatibi SM; Ozkan T; Zununi Vahed F; Nariman-Saleh-Fam Z; Pourghassem Gargari B; Sunguroglu A; Zununi Vahed S
Life Sci; 2019 Sep; 233():116680. PubMed ID: 31344431
[TBL] [Abstract][Full Text] [Related]
17. [Gut microbiota and immune crosstalk in metabolic disease].
Burcelin R
Biol Aujourdhui; 2017; 211(1):1-18. PubMed ID: 28682223
[TBL] [Abstract][Full Text] [Related]
18. Gut microbiota interactions with antitumor immunity in colorectal cancer: From understanding to application.
Zhuang YP; Zhou HL; Chen HB; Zheng MY; Liang YW; Gu YT; Li WT; Qiu WL; Zhou HG
Biomed Pharmacother; 2023 Sep; 165():115040. PubMed ID: 37364479
[TBL] [Abstract][Full Text] [Related]
19. The Impact of the Microbiome on Resistance to Cancer Treatment with Chemotherapeutic Agents and Immunotherapy.
Sevcikova A; Izoldova N; Stevurkova V; Kasperova B; Chovanec M; Ciernikova S; Mego M
Int J Mol Sci; 2022 Jan; 23(1):. PubMed ID: 35008915
[TBL] [Abstract][Full Text] [Related]
20. Microbiome dysbiosis in cancer: Exploring therapeutic strategies to counter the disease.
Sharma VR; Singh M; Kumar V; Yadav M; Sehrawat N; Sharma DK; Sharma AK
Semin Cancer Biol; 2021 May; 70():61-70. PubMed ID: 32693015
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
